Salute e Benessere

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and…

Year marked by growing body of promising data demonstrating Ampligen's potential to address multiple high-value indicationsCompany to host conference call and webcast today, April 2 ndat 8:30 AM ETOCALA, Fla., April02, 2024(GLOBE NEWSWIRE) --AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the full year 2023 and provided a business update. As previously announced, the Company will host a conference call and...

Orexo announces that the condition for early redemption of its existing bonds…

For further information on the early redemption, see the Company's press release on March 13, 2024, and the notice of early redemption which is available on the Company's website. For further information on the early redemption, see the Company's press release onMarch 13, 2024, and the notice of early redemption which is available on the Company's website. For further information please contact: Nikolaj Sørensen, President and CEO Fredrik Järrsten, EVP and CFOLena Wange, IR &...

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye…

LONDON and NEW YORK, April02, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry...

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1…

Evaxion and its collaborator tested Evaxion-designed vaccine antigens againstStaphylococcus aureus in a clinically relevant animal model of surgical site infectionsThe vaccine antigens significantly protected large, non-rodent animals against surgical site infections, indicating promising potential for clinical efficacy in human trials COPENHAGEN, Denmark, April02, 2024(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio...

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 2 April 2024– On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the...

Faszin Develops "Zero-Damage Hair Styling" Philosophy, the First of Its Kind

The first A stands for "Anti-Frizz" technology. It refers to Faszin's IonPeak system, a built-in ion generator that releases tens of millions of negative ions to flatten the hair cuticle and help it retain moisture. The first A stands for "Anti-Frizz" technology. It refers to Faszin's IonPeak system, a built-in ion generator that releases tens of millions of negative ions to flatten the hair cuticle and help it retain moisture. The second A refers to Faszin's…

FEP Heat Shrink Medical Tubing Market worth $208 million by 2029 - Exclusive…

Browse in-depth TOC on "FEP Heat Shrink Medical Tubing Market" Browse in-depth TOC on "FEP Heat Shrink Medical Tubing Market" 190 – Tables 49 – Figures 211 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=88280405 By Application, Catheter delivery devices accounted for the largest share in 2023. Catheter delivery devices are essential medical devices used in a wide range of diagnostic and therapeutic procedures, including...

Serotonin Supplement Market to Reach US$ 1,623.0 Million by 2034 Amid Growing…

Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19383 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-19383 The demand for serotonin supplements is increasing as the population ages and brain health awareness grows. The digital age and sedentary lifestyles contribute to cognitive deterioration in younger people,...

Sobi publishes Annual and sustainability report for 2023

Sobi's 2023 Annual and Sustainability Report is available on sobi.com. The Swedish Annual Report is also available in European Single Electronic Format (ESEF). Sobi's 2023 Annual and Sustainability Report is available on sobi.com. The Swedish Annual Report is also available in European Single Electronic Format (ESEF). Sobi Sobi ®is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to...

Crossject advances in its U.S. Strategy and reports Financial Results for 2023

Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE® in Q1 2025Expectation to complete U.S. New Drug Application (NDA) for ZEPIZURE® in H1 2025Reinforcement of supply chain [with addition of a second fill-and-finish CDMO]Reporting of a reduced Net loss of €8.5 million versus €11.2 million in 2022Dijon, France April 2, 2024, 10:30am CET...

CONCEPT MEDICAL RECEIVES US FDA IDE APPROVAL FOR MAGICTOUCH AVF INDICATION…

The Company has been granted four other US FDA IDE approvals for its MagicTouch product portfolio for different indications. The latest IDE approval for the AVF indication is their 5th in quick succession. The Company has been granted four other US FDA IDE approvals for its MagicTouch product portfolio for different indications. The latest IDE approval for the AVF indication is their 5 th in quick succession. This US FDA IDE approval allows Concept Medical to conduct pivotal clinical...

Grown Alchemist Completes Change of Ownership

"The L'OCCITANE Group has been an incredible partner and supporter of the business since its acquisition of a majority control in 2022, enabling us to establish a strong foundation for growth, a stellar team, investment in product enhancements and new market entries," said Teal, CEO of Grown Alchemist. "That being said, we see this acquisition of Grown Alchemist as an opportunity to accelerate brand growth, as we gain more strategic flexibility and autonomy outside of a listed…

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 2, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from March 25, 2024 to March 29, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...

Scantox closes the acquisition of QPS Neuropharmacology - now Scantox Neuro

"Since announcing the intended acquisition of QPS Neuropharmacology in November, we have worked intensely to prepare the expansion of our company. This is a transformational addition to our Discovery division, meaningfully changing our lead optimization platform and expanding the depth and breadth of our services in the CNS and rare disease area. The rapid growth journey of Scantox continues, providing our clients worldwide with a continuously enhanced level of service and scientific…

Clario announces acquisition of AI-powered software company ArtiQ

"We're thrilled to welcome ArtiQ into our organization," said Chris Fikry, Chief Executive Officer at Clario. "Since 2018, Clario has been a pioneer in applying artificial intelligence to improve the quality and efficiency of clinical trial execution. This move significantly advances AI within our respiratory portfolio. With ArtiQ's technology, we are expanding our ability to rapidly scale AI for overreading while ensuring data quality and streamlining the clinical trial process…

Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.

COPENHAGEN, Denmark, April 2, 2024– Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS ®by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both public and private payers. Since 2022, in response to the global mpox outbreak, JYNNEOS has been made available through public health channels for...

Tethis S.p.A. announces enrollment of the first two patients in a clinical study…

In the last few days, the first two Metastatic Breast Cancer (MBC) patients have been enrolled from a total cohort of twenty-five. Their blood samples were successfully processed using a See.d instrument at the European Institute of Oncology, generating plasma and cytology slides for further analytical characterization of cell-free DNA (cfDNA) and Circulating Tumor Cells (CTCs). The study will yield the first set of "real world" data on the performance and user-friendliness of Tethis'…

Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance

LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in…

OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid…

OSE Immunotherapeutics Announces Peer-Reviewed Publicationon Novel Myeloid Immune Checkpoint CLEC-1 inJournal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET –OSE ImmunotherapeuticsSA (ISIN: FR0012127173; Mnemo: OSE)today announced the publication of novel data in the peer-reviewedJournal of Immunology(1) on a first-in-class research program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy. The academic...

ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System

FDA clearance would allow the Company to market its breakthrough therapy to improve or restore hand and arm function after spinal cord injury in the US THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)EINDHOVEN, the Netherlands, April02, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to improve or restore...

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an…

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical developmentSTRO-003 targets ROR1, a clinically validated antibody drug conjugate (ADC) targetSTRO-003 has shown robust monotherapy efficacy and potential for a differentiated safety profile in preclinical development in solid tumors and hematological malignancies 1 PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024-...

C LADTEK GROUP: Building A Sustainability Future - 20 Years of Additive…

Cladtek uses Corrosion-Resistant Alloy (CRA) to manufacture mechanically lined pipe and weld overlay (Cladding) solutions specifically for the energy industry. Cladtek consistently emphasizes the importance of green and clean energy with minimal environmental impact and is actively working on energy transition projects including Geothermal, and Carbon Capture Utilization Storage (CCUS). Cladtek uses Corrosion-Resistant Alloy (CRA) to manufacture mechanically lined pipe and weld overlay...

Diabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5%…

Key Takeaways from the Diabetic Kidney Disease Market Report Key Takeaways from the Diabetic Kidney Disease Market Report Discover which therapies are expected to grab the major diabetic kidney disease market share @Diabetic Kidney Disease Market Report Diabetic Kidney Disease Overview Diabetic kidney disease (DKD), also referred to as diabetic nephropathy (DN), is a clinical condition marked by persistent albuminuria and a gradual decline in renal function. This term...

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

/48 thof the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company. About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment...

Altri Comunicati